The notion that companies can offset the impact of the 2.3% device excise tax scheduled to take effect in January by enacting pricing increases is unlikely to play out in reality, in most cases, industry watchers say.
Given anemic market growth trends, “most medical device companies will be unable to pass the device tax on to their...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?